Loading…
Loading…
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the closing of its previously announced global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Amova Asset Management Americas Inc. cut its position in shares of Nurix Therapeutics, Inc. (NASDAQ: NRIX) by 8.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,181,146 shares of the company's stock after selling 109,408 shares during
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to a loss of $0.52 per share a year ago.
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for NRIX and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.